Eton Pharmaceuticals to Report First Quarter Financial Results on Thursday, May 14, 2020
Eton Pharmaceuticals, Inc. (Nasdaq: ETON) will report its first quarter 2020 financial and operational results on May 14, 2020. A conference call and audio webcast will follow at 4:30 p.m. ET. Investors can access the live webcast on Eton's investor website or by calling specified numbers. Eton specializes in developing innovative drug products, focusing on hospital injectable and pediatric rare disease products. Its initial product, Biorphen, is the only FDA-approved ready-to-use phenylephrine injection, launched in December 2019. The lead pediatric product, Alkindi® Sprinkle, is currently under FDA review.
- Launch of Biorphen, the only FDA-approved ready-to-use formulation of phenylephrine injection.
- Alkindi® Sprinkle, a lead pediatric product, currently under FDA review.
- Development of eight additional products, with three undergoing FDA review.
- None.
DEER PARK, Ill., May 06, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report first quarter 2020 financial and operating results on Thursday, May 14, 2020. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 4:30 p.m. ET (3:30 p.m. CT).
The live webcast can be accessed on the investors section of Eton’s website at https://ir.etonpharma.com/. The conference call can be accessed by dialing 1-866-795-8473 (domestic) or 1-470-495-9161 (international) and refer to conference ID 8498986. An archived webcast will be available on Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.
About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, acquiring, and commercializing innovative products. Eton is primarily focused on hospital injectable and pediatric rare disease products. The company’s first commercial product, Biorphen, is the only FDA approved ready-to-use formulation of phenylephrine injection and was launched in December 2019. The company’s lead pediatric product is the orphan drug Alkindi® Sprinkle, which is currently under review with the FDA. The company has an additional eight products under development, including three that are under review with the FDA.
Investor Contact:
David Krempa
dkrempa@etonpharma.com
612-387-3740
FAQ
When will Eton Pharmaceuticals announce its first quarter 2020 results?
How can I access the Eton Pharmaceuticals conference call?
What is Eton Pharmaceuticals' first commercial product?
What is the status of Eton Pharmaceuticals' product Alkindi Sprinkle?
